Robust exchangeability designs for early phase clinical trials with multiple strata
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Clinical trials with multiple strata are increasingly used in drug development. They may sometimes be the only option to study a new treatment, for example in small populations and rare diseases. In early phase trials, where data are often sparse, good statistical inference and subsequent decision‐making can be challenging. Inferences from simple pooling or stratification are known to be inferior to hierarchical modeling methods, which build on exchangeable strata parameters and allow borrowing information across strata. However, the standard exchangeability (EX) assumption bears the risk of too much shrinkage and excessive borrowing for extreme strata. We propose the exchangeability–nonexchangeability (EXNEX) approach as a robust mixture extension of the standard EX approach. It allows each stratum‐specific parameter to be exchangeable with other similar strata parameters or nonexchangeable with any of them. While EXNEX computations can be performed easily with standard Bayesian software, model specifications and prior distributions are more demanding and require a good understanding of the context. Two case studies from phases I and II (with three and four strata) show promising results for EXNEX. Data scenarios reveal tempered degrees of borrowing for extreme strata, and frequentist operating characteristics perform well for estimation (bias, mean‐squared error) and testing (less type‐I error inflation). Copyright © 2015 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Gelman, A. (2006) · Bayesian Analysis · doi:10.1214/06-ba117a · Cited by 4,050
Random-effects model for meta-analysis of clinical trials: An update
DerSimonian, R., & Kacker, R. (2007) · Contemporary Clinical Trials · doi:10.1016/j.cct.2006.04.004 · Cited by 2,374
Testing a Point Null Hypothesis: The Irreconcilability of P Values and Evidence
Berger, J. O., & Sellke, T. (1987) · Journal of the American Statistical Association · doi:10.2307/2289131 · Cited by 548
Estimating a Population of Parameter Values Using Bayes and Empirical Bayes Methods
Louis, T. A. (1984) · Journal of the American Statistical Association · doi:10.1080/01621459.1984.10478062 · Cited by 218
Cited by
Beyond Randomized Clinical Trials: Use of External Controls
Schmidli, H., Häring, D. A., Thomas, M., Cassidy, A., Weber, S., & Bretz, F. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1723 · Cited by 125
Metadata
- Authors
- Neuenschwander, B., Wandel, S., Roychoudhury, S., & Bailey, S.
- Venue
- Pharmaceutical Statistics
- Publisher
- Wiley
- Published
- 2015-12-18
- Volume
- 15
- Issue
- 2
- Pages
- 123-134
- ISSN
- 1539-1604 (ISSN-L)
- 1539-1612
- OpenAlex
- W2216798916
- Cited by
- 175
- References
- 5
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Robust exchangeability designs for early phase clinical trials with multiple strata. https://app.cochat.ai/papers/10.1002/pst.1730
- The paper
- Neuenschwander, B., Wandel, S., Roychoudhury, S., & Bailey, S. (2016). Robust exchangeability designs for early phase clinical trials with multiple strata. Pharmaceutical Statistics. https://doi.org/10.1002/pst.1730
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.